Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.

Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields P, Gunawan A, Oliver R, Djebbari F, Booth S, McMillan A, Fox CP, Bishton MJ, Collins GP, Hatton CSR.

J Intern Med. 2019 Jun;285(6):681-692. doi: 10.1111/joim.12889. Epub 2019 Apr 11.

PMID:
30811713
2.

Complete remission of immunochemotherapy-refractory monomorphic post-transplant lymphoproliferative disorder mediated by endogenous T-cell recovery.

Bishton MJ, Long HM, Dowell AC, Meckiff BJ, Byrne C, Fox CP.

Leuk Lymphoma. 2019 Aug;60(8):2075-2078. doi: 10.1080/10428194.2019.1571203. Epub 2019 Feb 5. No abstract available.

PMID:
30721640
3.

Population-based study of mantle cell lymphoma: Improvements in survival only seen in younger patients.

Joshi K, Hubbard R, Bishton MJ.

Hematol Oncol. 2018 Jan 24. doi: 10.1002/hon.2495. [Epub ahead of print] No abstract available.

PMID:
29363157
4.

Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate.

Munir T, Bishton MJ, Carter I, McMillan A, O'Connor S, Sovani V, Haynes AP, Fox CP.

Clin Lymphoma Myeloma Leuk. 2016 Dec;16(12):705-712. doi: 10.1016/j.clml.2016.08.014. Epub 2016 Aug 10.

PMID:
27640075
5.

The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literature.

Jethwa KD, Bishton MJ, Fox CP.

Br J Haematol. 2017 Aug;178(3):476-479. doi: 10.1111/bjh.14130. Epub 2016 May 5. Review. No abstract available.

PMID:
27146257
6.

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.

Reyal Y, Kayani I, Bloor AJC, Fox CP, Chakraverty R, Sjursen AM, Fielding AK, Ben Taylor M, Bishton MJ, Morris EC, Thomson KJ, Russell N, Mackinnon S, Peggs KS.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14.

7.

Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee.

Bishton MJ, McMillan AK, Fox CP.

Br J Haematol. 2017 Apr;177(2):320-321. doi: 10.1111/bjh.14050. Epub 2016 Mar 28. No abstract available.

PMID:
27018322
8.

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

Bishton MJ, Hughes S, Richardson F, James E, Bessell E, Sovani V, Ganatra R, Haynes AP, McMillan AK, Fox CP.

Br J Haematol. 2016 Jan;172(2):246-54. doi: 10.1111/bjh.13831. Epub 2015 Nov 18.

PMID:
26577576
9.

Era-by-era improvement in survival for elderly patients with Hodgkin lymphoma; outcome data from a large population-based cohort.

Bishton MJ, Hubbard R, Witherall R, Jones SG, Richardson F, James EJ, Sovani V, Bessell EM, Haynes AP, McMillan AK, Fox CP.

Ann Oncol. 2015 Nov;26(11):2356-7. doi: 10.1093/annonc/mdv359. Epub 2015 Sep 15. No abstract available.

PMID:
26374286
10.

EBV-driven relapse of peripheral T-cell lymphoma, masquerading as a post transplant lymphoproliferative disorder following allo-SCT.

Fox CP, Bishton MJ, O'Connor S, Hughes S, Byrne JL, Russell N.

Bone Marrow Transplant. 2014 Jan;49(1):150-2. doi: 10.1038/bmt.2013.125. Epub 2013 Aug 12. No abstract available.

PMID:
23933761
11.

Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide.

Bishton MJ, Gardiner EE, Harrison SJ, Prince HM, Johnstone RW.

Thromb Res. 2013 Jun;131(6):514-20. doi: 10.1016/j.thromres.2013.02.013. Epub 2013 May 2.

PMID:
23642854
12.

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia.

Bishton MJ, Harrison SJ, Martin BP, McLaughlin N, James C, Josefsson EC, Henley KJ, Kile BT, Prince HM, Johnstone RW.

Blood. 2011 Mar 31;117(13):3658-68. doi: 10.1182/blood-2010-11-318055. Epub 2011 Feb 3. Erratum in: Blood. 2015 Jun 11;125(24):3824-5.

PMID:
21292776
13.

MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi).

Burbury KL, Bishton MJ, Johnstone RW, Dickinson MJ, Szer J, Prince HM.

Ann Hematol. 2011 Jul;90(7):847-9. doi: 10.1007/s00277-010-1099-6. Epub 2010 Oct 15. No abstract available.

PMID:
20949272
14.

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies.

Bishton MJ, Johnstone RW, Dickinson M, Harrison S, Prince HM.

Pharmaceuticals (Basel). 2010 Aug 17;3(8):2674-2688. Review.

15.

What is responsible for the recent improvements in outlook for patients with follicular lymphoma?

Bishton MJ, Seymour JF.

Leuk Lymphoma. 2010 Jun;51(6):960-2. doi: 10.3109/10428194.2010.493252. No abstract available.

PMID:
20536343
16.

Light chain deposition disease presenting as massive hepatomegaly.

Nath SV, Peiris M, Bishton MJ, Maxwell E, Prince HM.

Pathology. 2010 Apr;42(3):307-10. doi: 10.3109/00313021003631171. No abstract available.

PMID:
20350234
17.

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.

Prince HM, Bishton MJ, Johnstone RW.

Future Oncol. 2009 Jun;5(5):601-12. doi: 10.2217/fon.09.36. Review.

PMID:
19519200
18.

Clinical studies of histone deacetylase inhibitors.

Prince HM, Bishton MJ, Harrison SJ.

Clin Cancer Res. 2009 Jun 15;15(12):3958-69. doi: 10.1158/1078-0432.CCR-08-2785. Epub 2009 Jun 9. Review.

19.

Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab.

Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF.

Ann Oncol. 2008 Sep;19(9):1629-33. doi: 10.1093/annonc/mdn172. Epub 2008 Jun 2.

PMID:
18522934
20.

Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independent data set.

Bishton MJ, Hicks RJ, Prince HM, Ritchie DS, Wolf M, Seymour JF.

Leukemia. 2008 Dec;22(12):2259-60; author reply 2260-1. doi: 10.1038/leu.2008.116. Epub 2008 May 15. No abstract available.

PMID:
18480835
21.

A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.

Bishton MJ, Hicks RJ, Westerman DA, Prince MH, Wolf M, Seymour JF.

Haematologica. 2008 May;93(5):789-90. doi: 10.3324/haematol.12253. No abstract available.

22.

IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.

Fox CP, McMillan AK, Bishton MJ, Haynes AP, Russell NH.

Br J Haematol. 2008 Apr;141(2):244-8. doi: 10.1111/j.1365-2141.2008.07068.x.

PMID:
18353164
23.

Spinal epidural lipomatosis in myeloma.

Liew MS, Bishton MJ, Januszewicz H, Alatakis S, Prince HM.

Leuk Lymphoma. 2007 Oct;48(10):2068-70. No abstract available.

PMID:
17852706
25.

Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.

Bishton MJ, Haynes AP.

Br J Haematol. 2007 Jan;136(1):111-3. Epub 2006 Nov 20.

PMID:
17116129
26.

Opsoclonus myoclonus following allogeneic haematopoietic stem cell transplantation.

Bishton MJ, Das Gupta E, Byrne JL, Russell NH.

Bone Marrow Transplant. 2005 Nov;36(10):923. No abstract available.

PMID:
16113657

Supplemental Content

Loading ...
Support Center